Adjuvant anti-PD-1 therapy(nivolumab for resected stage IIIB-IV or pembrolizumab for resected stage III) or dabrafenib and trametinib for patients with resectedstage III BRAFV600E-mutant melanoma (not authorized in Spain). For patients with AJCC8 stage IIIA and SLN < 1 mm, adjuvant treatment is generally not recommended.Other options not EMA or FDA approved: Neoadjuvant nivolumab plus ipilimumab followedby adjuvant therapy based on pathologicalresponse and BRAF status.Neoadjuvant plus adjuvant pembrolizumab.Clinical trial. This evidence concerns the gene BRAF and melanoma.